Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cytokinetics

40.43
+0.10000.25%
Post-market: 40.430.00000.00%18:42 EDT
Volume:893.39K
Turnover:36.01M
Market Cap:4.79B
PE:-7.68
High:40.84
Open:39.98
Low:39.33
Close:40.33
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
Loading ...

BRIEF-Bayer Strengthens Cardiovascular Portfolio With Cytokinetics' Aficamten In Japan

Reuters
·
19 Nov 2024

BRIEF-Cytokinetics And Bayer Announce Exclusive Licensing Collaboration For Aficamten In Japan

Reuters
·
19 Nov 2024

Cytokinetics Inc - Bayer to Conduct Phase 3 Trial in Japanese Patients With Obstructive HCM

THOMSON REUTERS
·
19 Nov 2024

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

THOMSON REUTERS
·
19 Nov 2024

Cytokinetics Inc - Eligible for up to €490 Million in Commercial Milestones

THOMSON REUTERS
·
19 Nov 2024

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Positive Clinical Outcomes Drive Buy Rating for Cytokinetics’s Cardiac Myosin Modulators

TIPRANKS
·
18 Nov 2024

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

THOMSON REUTERS
·
16 Nov 2024

Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Cytokinetics’ Promising Future: Buy Rating Backed by Strong Pipeline and Strategic Positioning

TIPRANKS
·
11 Nov 2024

Cytokinetics initiates phase 1 clinical study of muscle troponin activator CK-089

seekingalpha
·
11 Nov 2024

Cytokinetics Doses First Participants in Study of Potential Muscular Dystrophy Treatment

MT Newswires Live
·
11 Nov 2024

BRIEF-Cytokinetics Announces Initiation Of Phase 1 Clinical Study Of CK-4015089

Reuters
·
11 Nov 2024

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

THOMSON REUTERS
·
11 Nov 2024

Cytokinetics (CYTK) Initiated with a Buy at RBC Capital

TIPRANKS
·
11 Nov 2024

Cytokinetics: Strategic Growth and Strong Financial Positioning Drive Buy Rating

TIPRANKS
·
11 Nov 2024

Cytokinetics started at outperform by RBC, valuation cited

seekingalpha
·
08 Nov 2024

Stock Track | Cytokinetics Soars on Bullish Analyst Coverage

Stock Track
·
08 Nov 2024

RBC Starts Cytokinetics With Outperform Rating, $80 Price Target

MT Newswires Live
·
08 Nov 2024

Cytokinetics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
08 Nov 2024

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."